logo

SION

Sionna TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

SION Profile

Sionna Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing therapeutics for cystic fibrosis

Pharmaceutical
--
02/07/2025
NASDAQ Stock Exchange
41
12-31
Common stock
21 Hickory Drive, Suite 500, Waltham, MA 02451
--
Sionna Therapeutics, Inc., was incorporated under the laws of the State of Delaware in August 2019. The company is a clinical-stage biopharmaceutical company whose mission is to revolutionize the current treatment model for cystic fibrosis patients by developing new drugs that normalize the function of cystic fibrosis transmembrane conductance regulator proteins and provide clinically meaningful benefits to patients with CF.